Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Alexandar Tzankov; Zijun Y. Xu-Monette; Marc Gerhard; Carlo Visco; Stephan Dirnhofer; Nora Gisin; Karen Dybkaer; Attilio Orazi; Govind Bhagat; Kristy L. Richards; Eric D. Hsi; William W L Choi; J. Han Van Krieken; Maurilio Ponzoni; Andrés J M Ferreri; Qing Ye; Jane N. Winter; John P. Farnen; Miguel A. Piris; Michael B. Møller; M. James You; Timothy Mcdonnell; L. Jeffrey Medeiros; Ken H. Young

doi:10.1038/modpathol.2013.214

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Alexandar Tzankov, Zijun Y. Xu-Monette, Marc Gerhard, Carlo Visco, Stephan Dirnhofer, Nora Gisin, Karen Dybkaer, Attilio Orazi, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W L Choi, J. Han Van Krieken, Maurilio Ponzoni, Andrés J M Ferreri, Qing Ye, Jane N. Winter, John P. Farnen, Miguel A. Piris, Michael B. MøllerM. James You, Timothy Mcdonnell, L. Jeffrey Medeiros, Ken H. Young

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

In order to address the debatable prognostic role of MYC rearrangements in diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, we evaluated MYC rearrangements by fluorescence in situ hybridization in 563 cases using break-apart probes and IGH/MYC dual-fusion probes. Concurrent BCL2 and BCL6 aberrations were also assessed. Data were correlated with clinicopathological variables and prognostic parameters. MYC rearrangements were observed in 39/432 evaluable cases (9%), including 4 rearrangements detectable only with the dual-fusion probes, 15 detectable only with the break-apart probes and 20 detectable with both dual-fusion probes and break-apart probes. MYC rearrangements correlated with germinal center B-cell origin (P=0.02), MYC protein expression (P=0.032), and larger tumor mass size (P=0.0003). Patients with MYC rearrangements were more likely to be treatment resistant (P

Original language	English
Pages (from-to)	958-971
Number of pages	14
Journal	Modern Pathology
Volume	27
Issue number	7
DOIs	https://doi.org/10.1038/modpathol.2013.214
Publication status	Published - 2014

Keywords

diffuse large B-cell lymphoma
FISH
germinal center B-cell
MYC
prognosis
rearrangement
translocation

ASJC Scopus subject areas

Pathology and Forensic Medicine
Medicine(all)

Access to Document

10.1038/modpathol.2013.214

Fingerprint Dive into the research topics of 'Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP'. Together they form a unique fingerprint.

Cite this

Tzankov, A., Xu-Monette, Z. Y., Gerhard, M., Visco, C., Dirnhofer, S., Gisin, N., Dybkaer, K., Orazi, A., Bhagat, G., Richards, K. L., Hsi, E. D., Choi, W. W. L., Van Krieken, J. H., Ponzoni, M., Ferreri, A. J. M., Ye, Q., Winter, J. N., Farnen, J. P., Piris, M. A., ... Young, K. H. (2014). Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 27(7), 958-971. https://doi.org/10.1038/modpathol.2013.214

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. / Tzankov, Alexandar; Xu-Monette, Zijun Y.; Gerhard, Marc; Visco, Carlo; Dirnhofer, Stephan; Gisin, Nora; Dybkaer, Karen; Orazi, Attilio; Bhagat, Govind; Richards, Kristy L.; Hsi, Eric D.; Choi, William W L; Van Krieken, J. Han; Ponzoni, Maurilio ; Ferreri, Andrés J M; Ye, Qing; Winter, Jane N.; Farnen, John P.; Piris, Miguel A.; Møller, Michael B.; You, M. James; Mcdonnell, Timothy; Medeiros, L. Jeffrey; Young, Ken H.

In: Modern Pathology, Vol. 27, No. 7, 2014, p. 958-971.

Research output: Contribution to journal › Article › peer-review

Tzankov, A, Xu-Monette, ZY, Gerhard, M, Visco, C, Dirnhofer, S, Gisin, N, Dybkaer, K, Orazi, A, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Ponzoni, M , Ferreri, AJM, Ye, Q, Winter, JN, Farnen, JP, Piris, MA, Møller, MB, You, MJ, Mcdonnell, T, Medeiros, LJ & Young, KH 2014, 'Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP', Modern Pathology, vol. 27, no. 7, pp. 958-971. https://doi.org/10.1038/modpathol.2013.214

Tzankov, Alexandar ; Xu-Monette, Zijun Y. ; Gerhard, Marc ; Visco, Carlo ; Dirnhofer, Stephan ; Gisin, Nora ; Dybkaer, Karen ; Orazi, Attilio ; Bhagat, Govind ; Richards, Kristy L. ; Hsi, Eric D. ; Choi, William W L ; Van Krieken, J. Han ; Ponzoni, Maurilio ; Ferreri, Andrés J M ; Ye, Qing ; Winter, Jane N. ; Farnen, John P. ; Piris, Miguel A. ; Møller, Michael B. ; You, M. James ; Mcdonnell, Timothy ; Medeiros, L. Jeffrey ; Young, Ken H. / Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. In: Modern Pathology. 2014 ; Vol. 27, No. 7. pp. 958-971.

@article{e79c5abea54b4f2997eb175704919c46,

title = "Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP",

abstract = "In order to address the debatable prognostic role of MYC rearrangements in diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, we evaluated MYC rearrangements by fluorescence in situ hybridization in 563 cases using break-apart probes and IGH/MYC dual-fusion probes. Concurrent BCL2 and BCL6 aberrations were also assessed. Data were correlated with clinicopathological variables and prognostic parameters. MYC rearrangements were observed in 39/432 evaluable cases (9%), including 4 rearrangements detectable only with the dual-fusion probes, 15 detectable only with the break-apart probes and 20 detectable with both dual-fusion probes and break-apart probes. MYC rearrangements correlated with germinal center B-cell origin (P=0.02), MYC protein expression (P=0.032), and larger tumor mass size (P=0.0003). Patients with MYC rearrangements were more likely to be treatment resistant (P",

keywords = "diffuse large B-cell lymphoma, FISH, germinal center B-cell, MYC, prognosis, rearrangement, translocation",

author = "Alexandar Tzankov and Xu-Monette, {Zijun Y.} and Marc Gerhard and Carlo Visco and Stephan Dirnhofer and Nora Gisin and Karen Dybkaer and Attilio Orazi and Govind Bhagat and Richards, {Kristy L.} and Hsi, {Eric D.} and Choi, {William W L} and {Van Krieken}, {J. Han} and Maurilio Ponzoni and Ferreri, {Andr{\'e}s J M} and Qing Ye and Winter, {Jane N.} and Farnen, {John P.} and Piris, {Miguel A.} and M{\o}ller, {Michael B.} and You, {M. James} and Timothy Mcdonnell and Medeiros, {L. Jeffrey} and Young, {Ken H.}",

year = "2014",

doi = "10.1038/modpathol.2013.214",

language = "English",

volume = "27",

pages = "958--971",

journal = "Modern Pathology",

issn = "0893-3952",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

AU - Tzankov, Alexandar

AU - Xu-Monette, Zijun Y.

AU - Gerhard, Marc

AU - Visco, Carlo

AU - Dirnhofer, Stephan

AU - Gisin, Nora

AU - Dybkaer, Karen

AU - Orazi, Attilio

AU - Bhagat, Govind

AU - Richards, Kristy L.

AU - Hsi, Eric D.

AU - Choi, William W L

AU - Van Krieken, J. Han

AU - Ponzoni, Maurilio

AU - Ferreri, Andrés J M

AU - Ye, Qing

AU - Winter, Jane N.

AU - Farnen, John P.

AU - Piris, Miguel A.

AU - Møller, Michael B.

AU - You, M. James

AU - Mcdonnell, Timothy

AU - Medeiros, L. Jeffrey

AU - Young, Ken H.

PY - 2014

Y1 - 2014

N2 - In order to address the debatable prognostic role of MYC rearrangements in diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, we evaluated MYC rearrangements by fluorescence in situ hybridization in 563 cases using break-apart probes and IGH/MYC dual-fusion probes. Concurrent BCL2 and BCL6 aberrations were also assessed. Data were correlated with clinicopathological variables and prognostic parameters. MYC rearrangements were observed in 39/432 evaluable cases (9%), including 4 rearrangements detectable only with the dual-fusion probes, 15 detectable only with the break-apart probes and 20 detectable with both dual-fusion probes and break-apart probes. MYC rearrangements correlated with germinal center B-cell origin (P=0.02), MYC protein expression (P=0.032), and larger tumor mass size (P=0.0003). Patients with MYC rearrangements were more likely to be treatment resistant (P

AB - In order to address the debatable prognostic role of MYC rearrangements in diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, we evaluated MYC rearrangements by fluorescence in situ hybridization in 563 cases using break-apart probes and IGH/MYC dual-fusion probes. Concurrent BCL2 and BCL6 aberrations were also assessed. Data were correlated with clinicopathological variables and prognostic parameters. MYC rearrangements were observed in 39/432 evaluable cases (9%), including 4 rearrangements detectable only with the dual-fusion probes, 15 detectable only with the break-apart probes and 20 detectable with both dual-fusion probes and break-apart probes. MYC rearrangements correlated with germinal center B-cell origin (P=0.02), MYC protein expression (P=0.032), and larger tumor mass size (P=0.0003). Patients with MYC rearrangements were more likely to be treatment resistant (P

KW - diffuse large B-cell lymphoma

KW - FISH

KW - germinal center B-cell

KW - MYC

KW - prognosis

KW - rearrangement

KW - translocation

UR - http://www.scopus.com/inward/record.url?scp=84903789487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903789487&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2013.214

DO - 10.1038/modpathol.2013.214

M3 - Article

C2 - 24336156

AN - SCOPUS:84903789487

VL - 27

SP - 958

EP - 971

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 7

ER -